Boehringer Ingelheim will build a biomanufacturing facility in Shanghai in a strategic alliance designed to cater for Pharmas nervous about setting up plants in China.
US CMO Ben Venue has restarted 'limited drug manufacturing' at its plant in Bedford, Ohio, but does not expect to start shipping product for several months.
Outsourcing-Pharma.com brings you a round-up of the latest contract manufacturing facility additions, including news from Boehringer Ingelheim, Cambridge Major Laboratories, and B. Braun Group.
More bad news for troubled CMO Ben Venue Laboratories after European regulators recommend that production of two more drugs – Caelyx and Ceplene – is relocated to other facilities.
Elan has entered into a development and manufacturing agreement with German pharmaceutical company, Boehringer Ingelheim, for antibody-based therapeutics.
Outsourcing-Pharma presents its latest round up of movements in the pharma outsourcing sector, including appointments at PPD, Coldstream Laboratories and MPI Research.
Kuehne + Nagel is providing Boehringer Ingelheim with temperature-controlled road transportation of medical products to Czech Republic, Poland, Hungary, Greece and Croatia.
CMO Kemwell is receiving technical assistance from Boehringer Ingelheim for the construction of its new biotech facility, which is designed to marry European technology with Indian low cost manufacturing.
Abraxis has licensed rights to use ProMetic’s protein technology in the development of four new biopharmaceuticals that it hopes will generate around $600m (€422.5m) in US sales.
Germany's Rentschler Biotechnologie and Boehringer Ingelheim have
inked a preferred partnership agreement to jointly offer customers
a more streamlined biopharmaceutical production option.
Boehringer Ingelheim has been forced to announce the planned
closure of a UK manufacturing site as a result of pricing pressures
that mean the firm is unable to produce unit dose vials (UDVs) at
the site cost-effectively.
Ablynx, one of the two main players in the miniature antibody
sector, has signed 'by far' the biggest deal in its history, to
help Boehringer Ingelheim develop up to ten so called 'Nanobodies'.
Boehringer Ingelheim is voluntarily recalling all worldwide
products containing clobutinol hydrochloride, which has been on the
market for 46 years, following a report questioning the drug's
safety.
The world's most prescribed product for chronic obstructive
pulmonary disease (COPD) could soon be formulated with a new
propellant-free device following an observational study on a soft
mist inhaler (SMI) that Boehringer Ingelheim...
Jacobs Engineering Group has inked a new contract with Boehringer
Ingelheim to provide technical and construction services for its
new bulk active pharmaceutical ingredient (API) facility being
built in Petersburg, Virginia, US.
Boehringer Ingelheim Roxane (BIRI) has integrated Multisorb's
sorbent packets in its moisture prevention system, reducing costs,
decreasing downtime, and increasing line speed.
British drug delivery firm Vectura has inked a deal with Boehringer
Ingelheim to develop a dry powder inhaler (DPI) for a range of
proprietary respiratory products of the German company,
intensifying competition in a burgeoning asthma...
Oracle has introduced a new software program to help pharma
companies integrate clinical data from multiple sources and
streamline regulatory compliance in the clinical development
process. Pharma giant Boehringer Ingelheim is the...
The interest in Syntonix' SynFusion and Transceptor technologies
intensified as Boehringer Ingelheim became the second
pharmaceutical company to use this technology to optimise its
therapeutic peptides for inhalation.
The chemicals subsidiary of Germany's Boehringer Ingelheim is
expanding its manufacturing capacity for the nasal decongestant
phenylephrine hydrochloride to tap into what it said is growing
demand worldwide.
German pharmaceutical company, Boehringer Ingelheim (BI) and Ark
Therapeutics have signed an agreement granting BI exclusive rights
to Ark's intellectual property in relation to BI therapies
affecting the renin-angiotensin system.
German biotech company Evotec OAI posted decreased third quarterly
revenues of €16.1 million, down 26 per cent compared to 2003.
Evotec's performance reflects the difficult operating environment
for companies supplying drug discovery...
Germany's Boehringer Ingelheim has revealed plans to buy a
microtechnology specialist - STEAG microParts - to get full control
of a novel inhaler for drug delivery into the lungs.
German biotechnology company TeGenero has signed up Boehringer
Ingelheim to make clinical trials of its antibody drug in a move
that reflects an emerging trend in the contract manufacturing
sector.
Boehringer Ingelheim doubles its biopharmaceutical production
capacity at a stroke with the completion of a new plant at its site
in Biberach, Germany; a similar expansion in Austria is also
underway.
